文献速递白血病

髓外白血病表现似实体瘤:器官部位化疗耐药的临床、组织学与遗传线索

Extramedullary leukemia behaving as solid cancer: clinical, histologic, and genetic clues to chemoresistance in organ sites.
PubMed 文献 · Am J Hematol · 2019-08-27

该先导研究通过组织学、免疫组化和RNA测序分析AML乳腺肿瘤,发现其与实体瘤(如浸润性小叶乳腺癌、结肠癌等)有显著组织学相似性。测序显示AML乳腺肿瘤较正常乳腺有2157个基因显著下调,其中859个基因与三阴性乳腺癌同样下调。研究提示种子-土壤交互可能解释白血病细胞在非骨髓部位获得实体瘤行为及化疗耐药。

要点

  • AML乳腺肿瘤组织学上与浸润性小叶乳腺癌及多种实体瘤高度相似。
  • AML乳腺肿瘤较正常乳腺有2157个基因显著下调,其中859个与三阴性乳腺癌共同下调。
  • 至少30个下调基因与乳腺癌不良预后相关,5个在AML骨髓研究中与不良预后相关。

核心结论

  • AML乳腺肿瘤采用实体瘤的临床和转移行为,种子-土壤交互可能解释白血病细胞在非骨髓部位获得实体瘤表型及化疗耐药。

研究设计与样本

  • 先导研究,对一系列AML乳腺肿瘤进行组织学、免疫组化和RNA测序分析。

主要发现

  • AML乳腺肿瘤显示与浸润性小叶乳腺癌几乎相同的单行排列结构模式,以及与结肠、胆囊和胰腺癌相似的致密促纤维增生性瘢痕样纤维化。
  • AML乳腺肿瘤较正常乳腺有2157个基因显著下调。
  • 与三阴性乳腺癌比较,AML乳腺肿瘤有859个基因同样下调,其中至少30个与乳腺癌不良预后相关,5个在AML骨髓研究中报道与不良预后相关。

临床怎么用

  • 认识白血病可能采用实体瘤表型,实施全身扫描和消融肿瘤治疗,可能降低持续高的骨髓耐药和治疗失败率。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent studies of leukemic tumors in individual extramedullary sites showed they adopt the clinical and metastatic behavior of solid cancers originating in those sites. To elucidate features of leukemic tumors that render them resistant to agents effective against marrow leukemia, we analyzed a series of AML breast tumors by histology, immunohistochemistry, and RNA sequencing. Striking histologic similarities to solid cancers were found: a single-filing architectural pattern virtually identical to that of invasive lobular breast carcinoma and dense desmoplastic keloid-like fibrosis similar to colon, gallbladder, and pancreas carcinomas. Sequencing found 2157 genes significantly downregulated in AML breast tumors compared to normal breast. Comparison to triple-negative breast cancer found 859 genes similarly downregulated. At least 30 of these genes have been associated with poor prognosis in breast cancers. Five were reported in AML marrow studies to correlate with poor prognosis. The findings of this pilot study suggest the seed-and-soil interaction recognized in solid cancer growth may help explain how leukemic cells, in some patients, adopt solid tumor behavior in non-marrow sites. Transformed cells that metastasize from tumor to marrow can impart chemoresistance and be an unrecognized cause of treatment failure and death. Further studies comparing leukemic tumor to simultaneous marrow could potentially identify biomarkers that predict extramedullary resistance and lead to new therapeutic targets. Recognizing the potential for leukemia to adopt solid tumor phenotype, and implementation of body scanning and ablative tumor treatment, could decrease the persistently high rates of marrow resistance and treatment failure.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Cunningham I, Hamele-Bena D, Guo Y, et al. Extramedullary leukemia behaving as solid cancer: clinical, histologic, and genetic clues to chemoresistance in organ sites. Am J Hematol. 2019. PMID: 31353508. doi:10.1002/ajh.25594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。